Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Clinical and radiographic predictors of the need for resection of the inferior vena cava during nephrectomy for patients with renal cell carcinoma and caval tumor thrombus

BJU Int. , Volume 114, Issue 4, October 2014, Pages 14-15

Cryoablation versus Partial Nephrectomy for Clinical T1b Renal Tumors: A Matched Group Comparative Analysis

European Urology, Volume 71, Issue 1, January 2017, Pages 111-117

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

European Urology, Volume 70, Pages 705-706

Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies

European Urology, Volume 68, Issue 3, September 2015, Pages 506-515

Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

Clinical Genitourinary Cancer, Volume 13, Issue 2, April 2015

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

JAMA Oncol. 2017 Sep 01, Issue 9, Pages 1249-1252

Previous